Testing IRE and an immunotherapy drug for advanced pancreatic cancer
Part of Cancer clinical trials.
This trial tests a new combination: a special electric field treatment (IRE) plus a dual-function antibody (PD-1/CTLA-4) for people with locally advanced pancreatic cancer that didn't respond to standard chemotherapy. The goal is to see if this approach can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your pancreatic cancer must be locally advanced (just around the pancreas, not spread to other organs) and confirmed by a biopsy.
- You must have already tried standard chemotherapy (called AG) and it either stopped working or caused bad side effects.
- You need to be well enough to get around and take care of yourself (ECOG score 0–2).
- Your blood counts, liver and kidney function must be within certain healthy ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This study looks back at people with advanced pancreatic cancer who received a treatment called IRE (a special type of ablation) along with immunotherapy. The goal is to see how well this combination works and how safe it is for patients whose cancer cannot be removed with surgery.
This trial tests a drug combination (AG and nimotuzumab) followed by a procedure called irreversible electroporation (IRE) to treat locally advanced pancreatic cancer that hasn't spread. It aims to see if this approach can help patients whose cancer can't be removed by surgery.
This Phase 2 study looks at whether adding immunotherapy to a procedure called irreversible electroporation can help treat stage III pancreatic cancer. You might be eligible if you have measurable tumors and can safely undergo the procedure.
Hear when a new Pancreatic Adenocarcinoma Locally Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.